REGNBy Calypso Research5 min read

Regeneron (REGN) Q4 2025 Earnings Analysis

Eylea Can't Fly High with a $3.9B Budget Cut

Key Takeaways

Regeneron (REGN) reported Q4 2025 earnings with revenue of $3.9B, representing a +2.5% year-over-year change. The stock moved -1.1% on earnings day.

The bull case: Strong pipeline expansion across multiple therapeutic areas secures long-term growth and competitive differentiation.

The bear case: Intensifying competition in anti-VEGF and immunology spaces pressures market share and profitability.

Financial Highlights

  • Revenue: $3.9B (+2.5% YoY)
  • Gross Profit: $3.3B (84.9% margin, -0.1% YoY)
  • Operating Income: $880M (22.7% margin, -3.5% YoY)
  • Net Income: $845M
  • TTM Revenue: $14.3B

Stock Performance

  • Earnings Day Move: -1.1%
  • Year-to-Date: +1.4%
  • 1-Year Return: +10.3%
  • vs. S&P 500 (since earnings): +14.2%
  • vs. Nasdaq (since earnings): +17.1%

View live REGN data, AI chat, and interactive debates on Calypso →

What Management Said

Here are the key debates and direct quotes from Regeneron's Q4 2025 earnings call:

Growth Trajectory and Competitive Landscape for Eylea HD

Sentiment: Positive

"Eylea HD represents a growing proportion of Regeneron Pharmaceuticals, Inc.'s total anti-VEGF franchise now contributing nearly half of total net sales. Following recent label enhancements to include monthly dosing in retinal vein occlusion, Eylea HD now has the broadest label and greatest dosing flexibility of any anti-VEGF medicine." — Leonard Schleifer
"We anticipate high single-digit sequential demand growth in the first quarter while Eylea demand is expected to decline at a double-digit rate based on competition and importantly, ongoing conversion to Eylea HD." — Marion McCourt

Dupixent's Long-Term Potential and Pipeline Expansion

Sentiment: Positive

"We have also a lot of exciting follow-on opportunities in this space particularly with our collection of what we hope will prove to be the best-in-class long-acting IL-13, IL-4, and IL-4/13 bispecifics." — Leonard Schleifer
"Dupixent is a very special approach... its incredible safety profile is underappreciated, unlike most other immunomodulators, it doesn't suppress overall immunity." — George Yancopoulos

Geographic Atrophy (GA) Competitive Advantages

Sentiment: Positive

"By providing more profound blockade, one might actually see better benefit. Another opportunity is our systemic approach, which may avoid the safety risks like retinal vasculitis seen with current treatments." — George Yancopoulos
"We will measure 15-letter loss of visual acuity as a prospective secondary endpoint, providing a critical lens on visual impact beyond lesion growth rate." — Ryan Crowe

Differentiation of PCSK9 and GLP-1/GIP Combination Therapy

Sentiment: Positive

"Imagine inventing a GLP-1 that in addition to delivering profound weight loss, could also lower bad cholesterol by 50% to 60%. It would create an important and differentiated opportunity." — Leonard Schleifer
"Let everybody else fight for an extra 1% or 2% in weight loss. We're going to give you 50% to 60% LDL lowering with the associated expected cardiovascular benefit." — George Yancopoulos

Advanced Oncology Pipeline and Libtayo's Expansion

Sentiment: Positive

"The advanced melanoma study is powered to demonstrate a benefit in PFS and overall survival comparable to or better than current combination standards of care." — George Yancopoulos
"Once we have the data for the metastatic melanoma and adjuvant trials, we will read it out shortly thereafter." — Ryan Crowe

Bull Case

Strong pipeline expansion across multiple therapeutic areas secures long-term growth and competitive differentiation.

Bear Case

Intensifying competition in anti-VEGF and immunology spaces pressures market share and profitability.

Looking Ahead

Investors will be closely watching Regeneron's next quarterly report for continued execution, particularly around growth Trajectory and Competitive Landscape for Eylea HD. With operating margins at 22.7%, margin trends will remain a focal point. The muted stock reaction on earnings day suggests the market is taking a wait-and-see approach, and the next earnings report will be a key catalyst for the stock.

Frequently Asked Questions

What was Regeneron's revenue in Q4 2025?

Regeneron reported Q4 2025 revenue of $3.9B, representing a +2.5% year-over-year change.

Did Regeneron beat earnings expectations in Q4 2025?

The stock moved -1.1% on earnings day, suggesting the results were roughly in line with market expectations. The current bull case centers on: Strong pipeline expansion across multiple therapeutic areas secures long-term growth and competitive differentiation.

What is the bull case for REGN stock?

The bull case for REGN centers on: Strong pipeline expansion across multiple therapeutic areas secures long-term growth and competitive differentiation.

What is the bear case for REGN stock?

The bear case for REGN centers on: Intensifying competition in anti-VEGF and immunology spaces pressures market share and profitability.

How has REGN stock performed since its Q4 2025 earnings?

REGN moved -1.1% on the day of its Q4 2025 earnings report, outperforming the S&P 500 by +14.2% since earnings. Year-to-date, the stock has returned +1.4%.

Browse all 400+ earnings reports →

Learn More

Analyze REGN in Real Time

This is a static snapshot. For live financial data, AI-powered chat, and interactive earnings debates for Regeneron and 400+ other stocks, explore the full platform.

Open REGN on Calypso →

Calypso is an AI-powered equity research platform used by investment teams to cut earnings research time by over 80%.